All In Biotech

Drug Trial Radar · NCT01223534

QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.

Comparison of Two Strategies for Therapeutic Decision-making in Tuberculosis Contact Tracing: a Standard Strategy Based on Tuberculin Skin Test (TST) Alone vs TST Combined With QuantiFERON®-TB Gold In-Tube (QFT-IT)

Last checked: Nov 19, 2026Latest source record: May 27, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 871 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

871

Actual

Start

Jul 2010

Primary completion

Feb 2016

Study completion Feb 2016

Sponsor

Lead sponsor
Hospital Universitari de BellvitgeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cellestis
First posted
Oct 19, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypothesis: a combined strategy of tuberculin skin test (TST) followed by QuantiFERON-TB Gold In-Tube (QFT-IT) to confirm positivity (tuberculosis infection,in contact-tracing study will allow avoiding unnecessary preventive treatment without increasing rates of tuberculosis cases among contacts screened. Aim of the study: to compare a combined strategy of the TST and the QFT-IT with TST alone for the diagnosis of tuberculosis infection and for therapeutic decision in contact tracing study. Design and setting: Prospective, multicentre, comparative study in 12 hospitals in Spain. Study population: 870 subjects, household contacts of patients with culture positive pulmonary and/or laryngeal tuberculosis will be randomized to one of two strategies: Arm A (standard practice), in which treatment decisions will be based on the TST result, and Arm B (experimental), in which treatment decisions will be based on the QFT result. Interventions: participants in arm A will undergo TST; participants in arm B will undergo TST, and, in case of a positive result, QFT-IT as well. Participants with positive TST (arm A) and positive QFT-IT (arm B) will be diagnosed with tuberculosis infection and will be treated with isoniazid for 6 months. All participants will be followed for two years. End-points of evaluation: development of tuberculosis and proportion of subjects for whom treatment is prescribed in each arm.

Conditions

  • Latent Tuberculosis Infection

Interventions

  • Preventive treatment with Isoniazid.Drug

    If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.

  • Preventive treatment with IsoniazidDrug

    If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Development of tuberculosis.Time frame: Assessment of primary end-point: 24 months after randomization.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bellvitge University Hospital, IDIBELL

    L'Hospitalet de Llobregat, Barcelona, Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.